Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions

This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).

This study population was chosen from a non-probability sample.

Inclusion Criteria:

• Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs.

Exclusion Criteria:

• All according to contraindications in the label especially:

  • Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
  • Participants with moderate or severe heart failure (NYHA class III/IV).
  • Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.